# Novel Interplay of KILN and MKL1 in Vascular Pathophysiology

> **NIH NIH R01** · AUGUSTA UNIVERSITY · 2021 · $423,500

## Abstract

Vascular smooth muscle cells (VSMCs) exhibit remarkable phenotypic plasticity, whereby differentiated
contractile VSMCs switch to a synthetic state under pathological conditions. Synthetic VSMCs are manifested
by their high susceptibility to inflammatory activation and loss of contractility, contributing largely to various
vascular disorders such as post-angioplasty restenosis and aneurysm. Targeting early activation of VSMC
inflammation may represent an attractive strategy to block vascular pathologies. However, molecular
mechanisms involving key regulator(s) that drive the proinflammatory VSMC phenotype are incompletely
understood. One possibility that has yet to be explored is the pervasive class of long noncoding RNAs
(lncRNAs). Through an unbiased RNA-seq study, we discovered a novel human-specific lncRNA, KILN, which
is enriched in proinflammatory VSMCs and diseased human vessels (aneurysm). RNA-seq revealed that loss
of KILN in cultured VSMCs suppresses expression of multiple inflammatory genes. Notably, KILN is highly
responsive to inflammatory insults in humanized Bacterial Artificial Chromosome (BAC) transgenic mice
carrying either KILN (BAC-KILN) or both KILN and its neighboring gene IL8 (BAC-KILN/IL8). Both transgenic
lines display an exacerbated inflammatory response triggered by vascular injury. These results support a
critical role of KILN in promoting VSMC inflammation and vascular disease. Mechanistically, KILN interacts
with MKL1, a potent transcriptional cofactor with a recognized role in transactivating VSMC contractile genes.
Intriguingly, Mkl1 null mice are protected from aneurysm formation and depletion of MKL1 in cultured VSMCs
impairs the proinflammatory gene program. These results suggest a potential link between MKL1 and KILN in
VSMC inflammation and vascular disease. Indeed, loss of KILN decreases MKL1 protein levels and MKL1/p65
physical interaction, the latter being critical for transactivation of proinflammatory genes. These exciting
preliminary findings support a central hypothesis that KILN interacts with MKL1 to stabilize MKL1 protein,
which potentiates MKL1/p65-activated VSMC inflammation and vascular pathologies. We propose two specific
aims to probe this hypothesis. Aim 1 will elucidate the regulation and function of KILN during pathological
vascular remodeling using BAC transgenic mice, and evaluate KILN expression in vessels and plasma
exosomes from aneurysm patients. Aim 2 will elucidate the molecular mechanism of KILN-mediated vascular
inflammation and disease involving KILN disruption of MKL1 ubiquitination to potentiate MKL1/p65
transactivation of the proinflammatory gene program. Successful completion of the proposed studies will define
a new molecular switch comprising a novel VSMC-enriched lncRNA (KILN) that associates with MKL1 for
VSMC inflammation and pathological vascular remodeling. These studies will advance our knowledge of
lncRNA and MKL1 vascular pathophysiology, potentially providing novel i...

## Key facts

- **NIH application ID:** 10219334
- **Project number:** 5R01HL122686-08
- **Recipient organization:** AUGUSTA UNIVERSITY
- **Principal Investigator:** Xiaochun Long
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $423,500
- **Award type:** 5
- **Project period:** 2014-04-01 → 2023-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10219334

## Citation

> US National Institutes of Health, RePORTER application 10219334, Novel Interplay of KILN and MKL1 in Vascular Pathophysiology (5R01HL122686-08). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10219334. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*
